Cost-Effectiveness Analysis of 4 Kinds of Nucleoside Treatment for Chronic Hepatitis B in 2 Years

Objective To evaluate the cost-effectiveness of 4 nucleosides(lamivudine,adefovir,telbivudine,and entecavirr) against chronic Hepatitis B and to find appropriate proposal.Methods The efficacy and cost of 200 patients who were treated over 2 years with chronic hepatitis B in our outpatient were calculated,including their serum ALT normalization,reductions in serum HBV DNA level,HBeAg loss and seroconversion and the rate of drug resistance.The cost of lamivudine,adefovir,telbivudine entecavir and cost-effectiveness was calculated.Results The four medicine all had better effective.Efficacy of lamivudine,adefovir dipivoxil,telbivudine and entecavir treatment were 7.8%,3.2%,35.8%,and 86%,respectively.The ratio of cost-effectiveness were 1 379.99,4 129.12,460.55,and 308.73 Yuan.As a benchmark to entecavir,each additional unit of effect of lamivudine,adefovir dipivoxil,telbivudine,need increased investment of 201.88,161.08,200.47 RMB,respectively.Conclusion Among the 4 medicine,Entecavir has the highest efficiency,lowest potency of C/E values,the best of cost-effectiveness in 2-years treatment of chronic hepatitis B.